This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (405) Postoperative Monitoring and Telemonitoring (191) Obstetrics, Gynecology, and Reproductive Medicine (332) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (216)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/66246, first published .
Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

Authors of this article:

Kyoko Kikuno1 Author Orcid Image ;   Ryuta Asada2 Author Orcid Image ;   Takuma Ishihara2 Author Orcid Image ;   Yoshimasa Bomoto3 Author Orcid Image ;   Saki Murase3 Author Orcid Image ;   Yoko Ueda3 Author Orcid Image ;   Tomomi Shiga3 Author Orcid Image ;   Yoh Hayasaki3 Author Orcid Image ;   Tatsuro Furui3 Author Orcid Image ;   Satoko Matsuzaki4 Author Orcid Image ;   Masahiko Takemura4 Author Orcid Image ;   Kazutoshi Matsunami5 Author Orcid Image ;   Makoto Kubo6 Author Orcid Image ;   Naoki Ito7 Author Orcid Image ;   Masanori Isobe3 Author Orcid Image ;   Ken-ichirou Morishige4 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Kikuno K, Asada R, Ishihara T, Morishige K, Chikazawa K, Furui T, Isobe M. Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial. Advances in Therapy 2025;42(12):6248 View